Klaus Podar

List of Publications by Year
in descending order

247 papers	16,902 citations	9786 73 h-index	14208 128 g-index
259 all docs	259 docs citations	259 times ranked	14776 citing authors

#	Article	IF	Citations
1	On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future. Expert Opinion on Pharmacotherapy, 2022, 23, 1425-1444.	1.8	1
2	Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans. Clinical Cancer Research, 2021, 27, 1641-1649.	7.0	21
3	Pathway-Directed Therapy in Multiple Myeloma. Cancers, 2021, 13, 1668.	3.7	15
4	The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology. Cancers, 2021, 13, 2326.	3.7	24
5	JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia, 2021, 35, 3509-3525.	7.2	19
6	Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). British Journal of Cancer, 2021, 125, 582-592.	6.4	4
7	Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. Cancers, 2021, 13, 4312.	3.7	11
8	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 2021, 21, 993.	2.6	8
9	Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers, 2021, 13, 7.	3.7	13
10	Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers, 2021, 13, 5154.	3.7	30
11	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity. Blood, 2021, 138, 2644-2644.	1.4	0
12	Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies. Blood, 2021, 138, 1598-1598.	1.4	0
13	Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study). Blood, 2021, 138, 1669-1669.	1.4	0
14	Selinexor for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2020, 21, 399-408.	1.8	46
15	Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2019, 24, 133-152.	2.4	20
16	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	27.0	460
17	Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e106-e107.	0.4	0
18	Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. Expert Opinion on Investigational Drugs, 2019, 28, 445-462.	4.1	13

#	Article	IF	Citations
19	Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast Cancer Research and Treatment, 2019, 173, 585-596.	2.5	14
20	Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02). Blood, 2019, 134, 696-696.	1.4	4
21	Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. Blood, 2019, 134, 4341-4341.	1.4	0
22	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy. Blood, 2019, 134, 4415-4415.	1.4	0
23	A role for bone turnover markers Î²-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2431-2438.	1.3	10
24	The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. Annals of Hematology, 2018, 97, 839-849.	1.8	7
25	Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. Pharmaceutics, 2018, 10, 202.	4.5	29
26	Choosing an appropriate salvage therapy for a patient with multiple myeloma. Expert Opinion on Pharmacotherapy, 2018, 19, 1511-1516.	1.8	1
27	Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opinion on Pharmacotherapy, 2017, 18, 1061-1079.	1.8	5
28	Adoptive cell therapy in multiple Myeloma. Expert Opinion on Biological Therapy, 2017, 17, 1511-1522.	3.1	19
29	The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia, 2017, 31, 1570-1581.	7.2	60
30	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget, 2017, 8, 67639-67650.	1.8	26
31	Targeting the immune niche within the bone marrow microenvironment: The rise of immunotherapy in Multiple Myeloma. Current Cancer Drug Targets, 2017, 17, 1-1.	1.6	15
32	Editorial: Multiple Myeloma Immunotherapies. Current Cancer Drug Targets, 2017, 17, 768.	1.6	0
33	Targeting the Bone Marrow Microenvironment. Cancer Treatment and Research, 2016, 169, 63-102.	0.5	12
34	The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Angiogenesis. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S77.	0.4	0
35	Prolyl Hydroxylase 3 Attenuates MCL-1â€“Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells. Cancer Research, 2016, 76, 2219-2230.	0.9	16
36	Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Research, 2016, 18, 26.	5.0	25

#	Article	IF	Citations
37	Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway. PLoS ONE, 2016, 11, e0150507.	2.5	13
38	Abstract 2912: The AP-1 transcription factor JunB promotes multiple myeloma cell proliferation, survival and drug resistance in the bone marrow microenvironment. , 2016, , .		0
39	The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Bone Marrow Angiogenesis. Blood, 2016, 128, 2091-2091.	1.4	0
40	Toward optimizing pomalidomide therapy in MM patients. Blood, 2015, 125, 3968-3969.	1.4	1
41	Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia, 2015, 29, 1555-1563.	7.2	48
42	Efficacy of Subcutaneous Bortezomib in the Management of Patients with Multiple Myeloma or Relapsed Mantle Cell Lymphoma. Clinical Medicine Insights Therapeutics, 2014, 6, CMT.S9308.	0.4	1
43	Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128â€“350 triggers MM cell death via c-Jun upregulation. Cancer Letters, 2014, 343, 286-294.	7.2	29
44	Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget, 2014, 5, 10237-10250.	1.8	22
45	Abstract 3383: JunB/AP-1 controls MM cell proliferation, survival and drug resistance in the bone marrow microenvironment. , 2014, , .		0
46	The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment. Blood, 2014, 124, 3446-3446.	1.4	2
47	New insights, recent advances, and current challenges in the biological treatment of multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, S35-S53.	3.1	9
48	Targeting Multiple Myeloma Tumor Angiogenesis: Focus on VEGF. , 2013, , 283-299.		1
49	Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 797-813.	1.6	8
50	MM-associated anemia: more than â€œcrowding outâ€•HSPCs. Blood, 2012, 120, 2539-2540.	1.4	1
51	GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo. Cancer Research, 2012, 72, 5374-5385.	0.9	64
52	Ask the Experts: Deriving new treatment strategies in multiple myeloma. International Journal of Hematologic Oncology, 2012, 1, 21-26.	1.6	0
53	Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opinion on Pharmacotherapy, 2012, 13, 473-494.	1.8	16
54	Targeting the Tumor Microenvironment: Focus on Angiogenesis. Journal of Oncology, 2012, 2012, 1-16.	1.3	93

#	Article	IF	Citations
55	Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1128â€“350 Triggers MM Cell Death Via c-Jun Upregulation. Blood, 2012, 120, 3959-3959.	1.4	0
56	The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. British Journal of Haematology, 2011, 155, 438-448.	2.5	65
57	Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies. Current Cancer Drug Targets, 2011, 11, 1005-1024.	1.6	21
58	HIF regulation in tumor progression and angiogenesis and potential therapeutic agents. Drugs of the Future, 2011, 36, 391.	0.1	0
59	Abstract 660: Inhibition of centrosomal clustering suppresses tumor growthin vivo. , 2011, , .		0
60	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic antiâ€myeloma activity in vitro and in vivo. British Journal of Haematology, 2010, 149, 537-549.	2.5	119
61	Targeting the Ubiquitin-proteasome System for the Treatment of Multiple Myeloma and Other Human Diseases. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2889.	0.4	0
62	A therapeutic role for targeting c-Myc/Hif-1- dependent signaling pathways. Cell Cycle, 2010, 9, 1722-1728.	2.6	72
63	Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism. Journal of Biological Chemistry, 2010, 285, 32596-32605.	3.4	42
64	The Evolution and Maintenance of the Multiple Myeloma Cell Clone within the Liquid Bone Marrow Compartment. , 2010, , 2799-2809.		0
65	The Pathophysiologic Role of the Bone Marrow Environment and its Niches in Multiple Myeloma. , 2010, , 2811-2819.		0
66	Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. Blood, 2010, 116, 1838-1838.	1.4	0
67	Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1Î±â€“Dependent Pathway in Multiple Myeloma. Cancer Research, 2009, 69, 5082-5090.	0.9	89
68	Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cellsin vitroandin vivo. Molecular Cancer Therapeutics, 2009, 8, 26-35.	4.1	57
69	Emerging therapies for multiple myeloma. Expert Opinion on Emerging Drugs, 2009, 14, 99-127.	2.4	48
70	Bortezomib induces canonical nuclear factor-ÎºB activation in multiple myeloma cells. Blood, 2009, 114, 1046-1052.	1.4	329
71	Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target. Cancer Cell, 2009, 16, 309-323.	16.8	242
72	Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 2009, 23, 10-24.	7.2	317

#	Article	IF	Citations
73	Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia, 2009, 23, 961-970.	7.2	65
74	Multiple myeloma. Lancet, The, 2009, 374, 324-339.	13.7	685
75	Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood, 2009, 113, 1513-1521.	1.4	65
76	Biologic sequelae of IÎºB kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood, 2009, 113, 5228-5236.	1.4	70
77	BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood, 2009, 114, 1813-1819.	1.4	51
78	CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-mafâ€“mediated interactions with bone marrow stromal cells. Blood, 2009, 113, 4309-4318.	1.4	75
79	Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood, 2009, 114, 3276-3284.	1.4	38
80	Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma.. Blood, 2009, 114, 1850-1850.	1.4	1
81	Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.. Blood, 2009, 114, 3848-3848.	1.4	4
82	Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).. Blood, 2009, 114, 295-295.	1.4	0
83	A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene, 2008, 27, 721-731.	5.9	114
84	Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy. Clinical Cancer Research, 2008, 14, 6955-6962.	7.0	58
85	The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood, 2008, 111, 3751-3759.	1.4	122
86	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 2008, 111, 1654-1664.	1.4	193
87	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood, 2008, 112, 1329-1337.	1.4	439
88	Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia. Blood, 2008, 112, 2948-2948.	1.4	2
89	Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma. Blood, 2008, 112, 3662-3662.	1.4	3
90	The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma. Blood, 2008, 112, 2766-2766.	1.4	0

#	Article	IF	Citations
91	Mcl-1 Fragment Mcl-1(128â€“350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity. Blood, 2008, 112, 2751-2751.	1.4	0
92	Canonical and Non Canonical Activation of Hedgehog Pathway in Multiple Myeloma. Blood, 2008, 112, 2748-2748.	1.4	0
93	Sp1 Transcription Factor as a Novel Therapeutic Target in Multiple Myeloma (MM). Blood, 2008, 112, 3664-3664.	1.4	0
94	Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. Blood, 2008, 112, 2648-2648.	1.4	10
95	Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling. Blood, 2008, 112, 2763-2763.	1.4	0
96	C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications. Blood, 2008, 112, 2750-2750.	1.4	4
97	CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity Via C-Maf-Mediated Interactions with Bone Marrow Stromal Cells (BMSCs). Blood, 2008, 112, 840-840.	1.4	1
98	Inhibition of VEGF Signaling Pathways in Multiple Myeloma and Other Malignancies. Cell Cycle, 2007, 6, 538-542.	2.6	57
99	The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opinion on Investigational Drugs, 2007, 16, 1693-1707.	4.1	48
100	Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma. Cancer Research, 2007, 67, 1680-1688.	0.9	56
101	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood, 2007, 110, 1656-1663.	1.4	106
102	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood, 2007, 109, 1220-1227.	1.4	144
103	Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood, 2007, 109, 1669-1677.	1.4	126
104	Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in WaldenstrÃ¶m macroglobulinemia. Blood, 2007, 109, 4964-4972.	1.4	100
105	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood, 2007, 110, 3744-3752.	1.4	144
106	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Review of Anticancer Therapy, 2007, 7, 551-566.	2.4	12
107	The malignant clone and the bone-marrow environment. Best Practice and Research in Clinical Haematology, 2007, 20, 597-612.	1.7	78
108	A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene, 2007, 26, 2374-2380.	5.9	207

#	Article	IF	Citations
109	Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of Î²-catenin/TCF pathway. Leukemia, 2007, 21, 535-540.	7.2	28
110	BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. British Journal of Haematology, 2007, 136, 414-423.	2.5	49
111	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. British Journal of Haematology, 2007, 138, 783-791.	2.5	102
112	Inhibition of the TGF-Î² Signaling Pathway in Tumor Cells. , 2007, 172, 77-97.		5
113	Niches Within the Multiple Myeloma Bone Marrow Microenvironment. Translational Medicine Series, 2007, , 61-74.	0.0	1
114	CS1, a New Surface Target on Multiple Myeloma (MM) Cells, Protects Myeloma Cells from Apoptosis Via Regulation of ERK1/2, AKT and STAT3 Signaling Cascades.. Blood, 2007, 110, 109-109.	1.4	2
115	Delineation of Canonical and Non-Canonical NF-ÎºB Pathways in Multiple Myeloma: Therapeutic Implications.. Blood, 2007, 110, 670-670.	1.4	2
116	Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.. Blood, 2007, 110, 2524-2524.	1.4	1
117	Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.. Blood, 2007, 110, 3507-3507.	1.4	12
118	Activation of B-Cell Maturation Antigen (BCMA) on Human Multiple Myeloma Cells by a Proliferation-Inducing Ligand (APRIL) Promotes Myeloma Cell Function in the Bone Marrow Microenvironment.. Blood, 2007, 110, 1503-1503.	1.4	0
119	Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.. Blood, 2007, 110, 2503-2503.	1.4	0
120	Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.. Blood, 2007, 110, 256-256.	1.4	0
121	Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment.. Blood, 2007, 110, 2522-2522.	1.4	0
122	BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.. Blood, 2007, 110, 2937-2937.	1.4	0
123	The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo.. Blood, 2007, 110, 2507-2507.	1.4	0
124	Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.. Blood, 2007, 110, 258-258.	1.4	0
125	Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1.. Blood, 2007, 110, 1501-1501.	1.4	0
126	Emerging Therapies for Multiple Myeloma. American Journal of Cancer, 2006, 5, 141-153.	0.4	2

#	Article	IF	Citations
127	Role of B-Cellâ€“Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. Cancer Research, 2006, 66, 6675-6682.	0.9	212
128	The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19478-19483.	7.1	189
129	Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity. Gastroenterology, 2006, 131, 1734-1742.	1.3	93
130	Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Letters, 2006, 233, 10-15.	7.2	25
131	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107, 4053-4062.	1.4	398
132	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. British Journal of Haematology, 2006, 132, 698-704.	2.5	4
133	Gene expression analysis of Bâ€lymphoma cells resistant and sensitive to bortezomib*. British Journal of Haematology, 2006, 134, 145-156.	2.5	94
134	MLN120B, a Novel IÎºB Kinase Î² Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. Clinical Cancer Research, 2006, 12, 5887-5894.	7.0	130
135	Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition. Journal of Biological Chemistry, 2006, 281, 18177-18183.	3.4	96
136	The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstromâ€™s Macroglobulinemia.. Blood, 2006, 108, 2496-2496.	1.4	2
137	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. Blood, 2006, 108, 3460-3460.	1.4	1
138	Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/Î²-Catenin Pathway.. Blood, 2006, 108, 5005-5005.	1.4	1
139	Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.. Blood, 2006, 108, 3426-3426.	1.4	0
140	MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.. Blood, 2006, 108, 1636-1636.	1.4	0
141	Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.. Blood, 2006, 108, 3410-3410.	1.4	0
142	The Jak2 V617F Oncogene Associated with Polycythemia Vera Requires a Functional FERM Domain for Transformation and for Expression of the Myc and Pim Proto-Oncogenes.. Blood, 2006, 108, 3611-3611.	1.4	2
143	The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.. Blood, 2006, 108, 5003-5003.	1.4	0
144	BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.. Blood, 2006, 108, 3440-3440.	1.4	0

#	Article	IF	Citations
145	p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma.. Blood, 2006, 108, 5042-5042.	1.4	0
146	Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).. Blood, 2006, 108, 3466-3466.	1.4	0
147	The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.. Blood, 2006, 108, 3452-3452.	1.4	1
148	Identification of Novel Antigens with Induced Immune Response in MGUS.. Blood, 2006, 108, 655-655.	1.4	0
149	In Vitro Generation of Highly Purified Functional Invariant NKT Cells in Multiple Myeloma: A Strategy for Immunotherapy.. Blood, 2006, 108, 5104-5104.	1.4	0
150	CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.. Blood, 2006, 108, 3494-3494.	1.4	5
151	Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.. Blood, 2006, 108, 3454-3454.	1.4	0
152	Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma.. Blood, 2006, 108, 3415-3415.	1.4	0
153	Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma.. Blood, 2006, 108, 3474-3474.	1.4	0
154	Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood, 2005, 105, 350-357.	1.4	29
155	The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood, 2005, 105, 1383-1395.	1.4	310
156	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood, 2005, 106, 1794-1800.	1.4	167
157	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood, 2005, 106, 706-712.	1.4	54
158	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology, 2005, 128, 192-203.	2.5	305
159	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-Î² inhibitors. Oncogene, 2005, 24, 3121-3129.	5.9	43
160	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene, 2005, 24, 5888-5896.	5.9	56
161	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 2005, 8, 407-419.	16.8	673
162	Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma. Cancer Research, 2005, 65, 5898-5906.	0.9	146

#	Article	IF	Citations
163	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40â€“Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications. Cancer Research, 2005, 65, 11712-11720.	0.9	163
164	FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance. Cancer Research, 2005, 65, 7478-7484.	0.9	97
165	Targeting signalling pathways for the treatment of multiple myeloma. Expert Opinion on Therapeutic Targets, 2005, 9, 359-381.	3.4	33
166	A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells. Cancer Research, 2005, 65, 8350-8358.	0.9	147
167	Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma. Clinical Cancer Research, 2005, 11, 4251-4258.	7.0	93
168	Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood, 2005, 105, 1717-1723.	1.4	208
169	Cytokines and signal transduction. Best Practice and Research in Clinical Haematology, 2005, 18, 509-524.	1.7	78
170	The PKC- Inhibitor Enzastaurin Inhibits MM Cell Growth, Survival and Migration in the Bone Marrow Microenvironment.. Blood, 2005, 106, 1584-1584.	1.4	2
171	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. Blood, 2005, 106, 3378-3378.	1.4	1
172	Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone.. Blood, 2005, 106, 4447-4447.	1.4	1
173	The JAK Inhibitor INCB20 Induces Antiproliferative and Apoptotic Effects in Human Myeloma Cells In Vitro and In Vivo.. Blood, 2005, 106, 3357-3357.	1.4	0
174	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. Blood, 2005, 106, 5150-5150.	1.4	0
175	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. Blood, 2005, 106, 627-627.	1.4	0
176	R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma.. Blood, 2005, 106, 1580-1580.	1.4	0
177	Targeting Src- Family Kinase Activation and Downstream Molecular Events To Overcome MM Cell Growth, Survival, and Drug- Resistance.. Blood, 2005, 106, 1583-1583.	1.4	1
178	In Vitro Generation of Highly-Purified Functional Invariant NKT Cells: A Strategy for Immunotherapy in Multiple Myeloma.. Blood, 2005, 106, 5183-5183.	1.4	0
179	Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells.. Blood, 2005, 106, 1585-1585.	1.4	0
180	The Jak2V617F Oncogene Associated with Polycythemia Vera Regulates G1/S-Phase Transition.. Blood, 2005, 106, 3510-3510.	1.4	0

#	Article	IF	Citations
181	Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.. Blood, 2005, 106, 250-250.	1.4	1
182	Mcl-1 Regulation and Its Role in Multiple Myeloma. Cell Cycle, 2004, 3, 1259-1262.	2.6	125
183	Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma. Cancer Research, 2004, 64, 8746-8753.	0.9	30
184	Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells. Journal of Biological Chemistry, 2004, 279, 21658-21665.	3.4	60
185	Transforming Growth Factor Î² Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. Clinical Cancer Research, 2004, 10, 7540-7546.	7.0	111
186	Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. Cancer Research, 2004, 64, 2846-2852.	0.9	126
187	Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib. Cancer Research, 2004, 64, 7500-7506.	0.9	86
188	Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene, 2004, 23, 3597-3602.	5.9	54
189	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene, 2004, 23, 8766-8776.	5.9	127
190	2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis: an International Journal on Programmed Cell Death, 2004, 9, 149-155.	4.9	28
191	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic antiâ€“multiple myeloma (MM) activity and overcome bortezomib resistance. Blood, 2004, 103, 3158-3166.	1.4	122
192	GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood, 2004, 103, 3474-3479.	1.4	87
193	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood, 2004, 104, 2458-2466.	1.4	79
194	VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood, 2004, 104, 2886-2892.	1.4	147
195	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 2004, 104, 4188-4193.	1.4	177
196	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. Blood, 2004, 104, 2405-2405.	1.4	3
197	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. Blood, 2004, 104, 2456-2456.	1.4	1
198	Vascular Endothelial Growth Factor (VEGF) Is a Growth and Survival Factor in Waldenstromâ€™s Macroglobulinemia.. Blood, 2004, 104, 4892-4892.	1.4	2

#	Article	IF	Citations
199	Pim Kinases Mediate Viability Signals Downstream of the Tyrosine Kinase Oncogenes BCR-ABL and FLT3-ITD.. Blood, 2004, 104, 557-557.	1.4	0
200	Effects of the Indazolylpyrimidine GW786034 on Angiogenesis and MM Cell Growth: Therapeutic Implications.. Blood, 2004, 104, 2452-2452.	1.4	0
201	Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.. Blood, 2004, 104, 1498-1498.	1.4	2
202	Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. Blood, 2004, 104, 2401-2401.	1.4	0
203	JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.. Blood, 2004, 104, 3413-3413.	1.4	3
204	VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis.. Blood, 2004, 104, 631-631.	1.4	0
205	Combination of the mTOR Inhibitor Rapamycin and Revlimidâ„¢ (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).. Blood, 2004, 104, 1492-1492.	1.4	1
206	TGF-Î² Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2355-2355.	1.4	1
207	Lack of Mcl-1 Confers Resistance to Bortezomid in Multiple Myeloma.. Blood, 2004, 104, 2445-2445.	1.4	0
208	Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.. Blood, 2004, 104, 285-285.	1.4	1
209	Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-Î² Inhibitors.. Blood, 2004, 104, 2411-2411.	1.4	0
210	Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma.. Blood, 2004, 104, 3456-3456.	1.4	0
211	P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.. Blood, 2004, 104, 3348-3348.	1.4	0
212	Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.. Blood, 2004, 104, 644-644.	1.4	0
213	Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies.. Blood, 2004, 104, 2354-2354.	1.4	1
214	Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (VelcadeÂ®).. Blood, 2004, 104, 2453-2453.	1.4	1
215	A Novel Inosine Monophosphate Dehydrogenase Inhibitor VX-944 Overcomes Conventional Drug-Resistance in Multiple Mueloma Cells in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2468-2468.	1.4	1
216	Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. Blood, 2004, 104, 764-764.	1.4	0

#	Article	IF	Citations
217	The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.. Blood, 2004, 104, 3352-3352.	1.4	1
218	Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia, 2003, 17, 41-44.	7.2	173
219	Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene, 2003, 22, 6296-6300.	5.9	54
220	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene, 2003, 22, 8386-8393.	5.9	163
221	JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells. Journal of Biological Chemistry, 2003, 278, 17593-17596.	3.4	180
222	Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells. Journal of Biological Chemistry, 2003, 278, 5794-5801.	3.4	128
223	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 2003, 101, 1530-1534.	1.4	533
224	Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood, 2003, 101, 3606-3614.	1.4	67
225	Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood, 2003, 102, 3379-3386.	1.4	147
226	CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3â€“kinase/AKT/NF-Î²B signaling. Blood, 2003, 101, 2762-2769.	1.4	111
227	A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Research, 2003, 63, 5462-9.	0.9	189
228	Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Research, 2003, 63, 5850-8.	0.9	159
229	Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Research, 2003, 63, 6174-7.	0.9	184
230	Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Research, 2003, 63, 8428-36.	0.9	54
231	Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with Î²1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCÎ± Activation. Journal of Biological Chemistry, 2002, 277, 7875-7881.	3.4	161
232	Dephosphorylation of Ser-259 Regulates Raf-1 Membrane Association. Journal of Biological Chemistry, 2002, 277, 7913-7919.	3.4	108
233	CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood, 2002, 99, 1419-1427.	1.4	83
234	2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood, 2002, 100, 2187-2194.	1.4	110

#	Article	IF	Citations
235	Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell, 2002, 1, 479-492.	16.8	327
236	Translocation of Ku86/Ku70 to the multiple myeloma cell membrane. Experimental Hematology, 2002, 30, 212-220.	0.4	40
237	Î²-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Experimental Hematology, 2002, 30, 711-720.	0.4	31
238	Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene, 2002, 21, 1346-1358.	5.9	170
239	The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Research, 2002, 62, 5019-26.	0.9	128
240	The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Molecular Cancer Therapeutics, 2002, 1, 539-44.	4.1	101
241	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 2001, 98, 210-216.	1.4	869
242	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood, 2001, 98, 428-435.	1.4	399
243	Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 2001, 15, 1950-1961.	7.2	536
244	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology, 2001, 28, 607-612.	2.2	164
245	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology, 2001, 28, 607-612.	2.2	130
246	Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage. Journal of Immunology, 2000, 165, 6347-6355.	0.8	45
247	Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation. Journal of Biological Chemistry, 2000, 275, 22300-22304.	3.4	200